Volume 25, Number 10—October 2019
Research
Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus
Table 2
Characterization of MERS-CoV–negative control serum panel included in study of serologic assays for MERS-CoV*
Name | Recombinant spike protein–based indirect immunofluorescence test, reciprocal endpoint titers* |
|||||
---|---|---|---|---|---|---|
HCoV-229E | HCoV-NL63 | HCoV-OC43 | HCoV-HKU1 | SARS-CoV | MERS-CoV | |
WHO/A | 160 | 1,280 | 320 | 640 | NR | NR |
WHO/B | 2,560 | 1,280 | 1,280 | 160 | NR | NR |
WHO/C | 160 | 320 | 1,280 | 320 | NR | NR |
WHO/D | 1,280 | 2,560 | 320 | 160 | NR | NR |
WHO/E | 320 | 1,280 | 160 | 160 | NR | NR |
WHO/F | 80 | 320 | 320 | 160 | NR | NR |
WHO/G | 320 | 320 | 1,280 | 1,280 | NR | NR |
*All serum samples were tested in a dilution range of 1:20 to 1:5,120. CoV, coronavirus; HCoV, human CoV; MERS, Middle East respiratory syndrome; NR, nonreactive at the cutoff serum dilution of 1:20; SARS, severe acute respiratory syndrome; WHO, World Health Organization.
1Study participants who contributed data are listed at the end of this article.